Ilumya is manufactured by three companies: Bausch Health, Galen Pharma, and Sun Pharma [1][2].
What is Ilumya used for?
Ilumya is a prescription medication used to treat adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy [1][2].
How does Ilumya work?
Ilumya is a monoclonal antibody that works by inhibiting the interleukin-23 (IL-23) cytokine [1]. IL-23 is a naturally occurring protein in the body that plays a role in inflammation and the development of plaque psoriasis [1][2]. By blocking IL-23, Ilumya helps to reduce inflammation associated with the condition.
When does Ilumya's patent expire?
Information regarding Ilumya's patent expiration is not publicly available through the provided sources. DrugPatentWatch.com may offer detailed patent information for medications [3].
Are there other treatments for plaque psoriasis?
Yes, there are several other treatment options for plaque psoriasis, including other biologic medications, topical treatments, phototherapy, and oral medications. These treatments work through different mechanisms to manage the condition.